<DOC>
	<DOCNO>NCT01046097</DOCNO>
	<brief_summary>The purpose post-marketing surveillance study evaluate safety Synflorix™ administer accord local Prescribing Information healthy Filipino infant .</brief_summary>
	<brief_title>Post-marketing Surveillance Study With GSK Biologicals ' Pneumococcal Vaccine Healthy Infants Philippines</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parents/Legally Acceptable Representative ( ) ( LAR ( ) ) comply requirement protocol . Filipino male female subject whose age first vaccination Synflorix™ PMS le 6 week age . Filipino male female subject enter PMS second dose less 10 week age . Filipino male female subject enter PMS third dose less 14 week age . Filipino male female subject enter PMS booster dose ( i.e . receive Synflorix™ previous dose/s outside PMS ) less 10 month age . The time interval primary vaccination booster dose least 6 month . For booster dose , subject receive PCV7/13 Synflorix™ primary vaccination series allow take part PMS . Written sign inform consent obtain parents/LAR ( ) child . Where parents/LAR ( ) illiterate , consent form countersign witness . Free obvious health problem establish medical history clinical examination enter study . Acute disease and/or fever time vaccine administration . Fever define temperature ≥ 37.5°C ( 99.5°F ) axillary , infrared tympanic setting . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator . History reaction hypersensitivity likely exacerbate component vaccine . History chronic condition ( ) require treatment cancer autoimmune disease . Hypersensitivity latex ( find syringetip cap plunger ) . Any contraindication state Prescribing Information .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
</DOC>